Ketryx, an AI-native compliance platform for safety-critical product development, today announced record momentum entering 2026, following a year in which the company surpassed serving 100 million patients and demonstrated that safety-critical product development can be accelerated. As medical device, digital health, diagnostics, and life sciences organizations move from AI experimentation to enterprise-wide deployment, four of the top five Fortune 500 MedTech companies now run on Ketryx.
The company's platform addresses the growing need for validated AI in regulated industries. According to the announcement, Ketryx AI Agents reduce manual work by 90 percent and close compliance gaps, enabling faster release cycles without disrupting existing workflows. The platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles.
Ketryx's momentum reflects broader industry trends. Regulators worldwide are increasingly scrutinizing AI in medical devices, making compliance a critical factor for market access. By embedding compliance into the development process, Ketryx helps companies meet regulatory requirements while maintaining speed. The company's success with top MedTech firms suggests that its approach resonates with organizations seeking to balance innovation with safety.
For more information, visit www.ketryx.com. The full announcement, including downloadable images and bios, is available here.
